Our Business

Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group

We are committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and women’s health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth.

The company was first established nearly 70 years ago in Malmö, Sweden by Dr Frederik Paulsen and his wife Eva Paulsen, who named the company after the strong, closely-knit community of people originating from the island of Föhr who called themselves Feringers and spoke Fering. Together they pioneered the development of products based upon natural peptide hormones produced by the body’s own pituitary glands.  This legacy has served us well. Today, peptides remain the backbone of many of our therapeutic treatments, and Ferring’s own resilient, global community is committed to developing personalised, patient-centric treatments that work on the body’s own terms.  

Ferring employs more than 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.

As a privately owned business we take pride in being able to make the right decisions for the business at the right time. Not only does this remove the short-pressures of quarterly business results, but it also has a positive effect on how Ferring colleagues approach their work days. There is certainty built in to our work. This is the benefit of retaining a long-term perspective, an asset essential to doing good science.

 

‘Our business has been steadily 
evolving over the last ten years
from 
one of a more classic
pharmaceutical approach to one
increasingly focused on our true
value to society.’

Per Falk
President and Chief Science Officer

A strategy that responds to changing needs

The ever-changing dynamics of our industry keeps us on our toes. For many years we have focused on our peptides research and life-cycle management, a legacy which has stood the test of time. However, against a backdrop of ageing populations in key markets, changing lifestyles and corresponding changes in disease demographics, we have to be alive to the evolving needs of patients and to respond in kind. 

For example, the growth of chronic diseases demands that we pay more attention to specific disease areas and accompany our patients on longer and more tailored therapeutic journeys. Technology and improved access to information means that patients are better and more readily informed than ever. This demands of us an ability to adapt both the way we do research as well as the way we work with our patients.

Focus on patient-centricity

In recognition of our need to respond more effectively to patients, we have created a new role in the organisation focused on patient-centricity. Ed Trott, our new Chief Patient Officer (CPO) is charged with developing a strategy that goes beyond the traditional forms of patient involvement and advocacy and puts the patient back into the centre of our business (please click here for more details).

New growth, new opportunities

The emergence of new and dynamic growth areas such as gene therapy, microbiome therapy and the growing challenges over antibiotics resistance offer Ferring new opportunities – both to leverage its own existing strengths and build on the strengths of others, and to reach our patients with innovative treatments.

In April 2018, Ferring announced its acquisition of Rebiotix, a company dedicated to harnessing the power of the human microbiome. Both companies share a common commitment to exploring and understanding the human microbiome to develop new solutions for patients suffering from a range of chronic diseases, including paediatric ulcerative colitis (UC), multidrug-resistant urinary tract infections (UTIs) and Clostridium difficile Infection (CDI), a chronic illness caused by bacteria that infects the bowels and causes diarrhoea.1 Rebiotix’s proprietary Microbiota Restoration Therapy™ (MRT™) drug platform delivers healthy, live, human-derived microbes into the gastrointestinal tract in a ready-to-use, easy-to-administer form. One of its leading therapies, RBX2660 is in Phase 3 development.

Our global capabilities and reach mean that if approved we can enable better access for patients to this treatment and any future-approved human microbiome treatments. This offers a chance for a better quality of life for patients worldwide and lends strategic value to Ferring’s leadership in gastroenterology.

 

‘Our role is to understand
the realities of the patient’s
journey and to accompany
them on that journey.’ 

Ed Trott
Chief Patient Officer

 

Collaborative partnerships for better value and better outcomes

It is our belief that collaborative partnerships are the best way to create value for both patients, the public purse, and all of the stakeholders involved in delivering our therapies along the way – from research partners through to doctors on the frontline.

Ferring is also supported by other ongoing partnerships with world-leading research organisations in the field of microbiome research including the Karolinska Institute and Science for Life Laboratory, the Centre for Translational Microbiome Research, Intralytix, The Pasteur Institute, the University of Lille, MyBiotics Pharma, March of Dimes and Metabogen. In addition, Ferring also has an ongoing partnership with Roche on personalised fertility treatment, and with the World Health Organization (WHO) and MSD for Mothers to provide access to Ferring’s heat-stable carbetocin to prevent post-partum haemorrhage.

 

Looking ahead

We aspire to be a business that brings better and more patient-centric solutions to those who need them. Our strategy for doing this is to:

  • Address patient, provider and payer needs through innovation and lifecycle management that creates both value and better access.

  • Develop a sustainable pipeline of new molecules, sourcing peptides internally, proteins both internally and externally, and biologics externally. 

  • Leverage our existing global commercial and scientific expertise and identify external late stage projects and products that strengthen our portfolio. 

  • Attract and retain world-class talent who identify with our values and our purpose.